Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Coherus, In Ring As A Biosimilar Contender, Hopes To Smack Down Humira

Executive Summary

Six-year-old biosimilar specialist could be first company to launch a biosimilar version of Neulasta, but the possibility of a biosimilar version of Humira has investors ogling.

Advertisement

Related Content

Coherus Knocks Out One Humira Patent But Others Block Biosimilars
Can Biosimilar Studies Be Conducted Solely In Healthy Volunteers?
Apotex Moves To Block Coherus' Neulasta Biosimilar; Asks FDA To Require Patient Studies
Biosimilar Trade Secrets: Coherus Hiring Of Amgen Exec Leads To Theft Suit
Amgen's Amjevita Approved As First Biosimilar To AbbVie's Humira
FDA Biosimilar Policy Continues To Evolve With Approval Of Sandoz Erelzi
AbbVie v. Amgen Round One: Humira Biosimilar Infringes 10 Patents, Suit Claims
Biosimilar Litigation: Battles Continue Over Launch Notification, Access To FDA Info
Biosimilars Still Flummoxed By Neulasta: Sponsors Now 0 For 2 At FDA
Sandoz Skips Enbrel Biosimilar Patent Dance, Spurs Infringement Suit

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC097501

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel